CASE REPORT

Cushing’s syndrome as a rare manifestation of adrenal tumours in infants – case report

Jagoda Badurowicz¹, Joanna Stefanowicz¹,², Michalina Jeziorska¹,², Aleksandra Janecka¹,², Dorota Birkholz-Walerzak³,⁴, Andrzej Gołębiewski⁵, Maciej Piskunowicz⁶,⁷, Dominik Świętoń⁶,⁷

¹Department of Paediatrics, Haematology, and Oncology, University Clinical Centre, Gdansk, Poland
²Department of Paediatrics, Haematology, and Oncology, Faculty of Medicine, Medical University of Gdansk, Poland
³Department of Paediatrics, Diabetology, and Endocrinology, Faculty of Medicine, Medical University of Gdansk, Poland
⁴Department of Paediatrics, Diabetology, and Endocrinology, University Clinical Centre, Gdansk, Poland
⁵Department of Surgery and Urology for Children and Adolescents, Faculty of Medicine, Medical University of Gdansk, Poland
⁶Department of Radiology, Faculty of Health Sciences, Medical University of Gdansk, Poland
⁷Department of Radiology, University Clinical Centre, Gdansk, Poland

ABSTRACT

We report a case of a six-week-old male infant with a congenital tumour of the left suprarenal gland. The tumour was diagnosed by ultrasound examination (USG) as a neonatal suprarenal mass. By the third month of life, the patient had typical signs of Cushing’s syndrome. Based on the results of hormonal tests and imaging studies (USG and MRI), an adrenocortical tumour was suspected. The patient could only be cured by surgery. Histopathological examination confirmed clinical diagnosis of an adrenocortical tumour. We concluded that Cushing’s syndrome may be a rare clinical manifestation of adrenal tumour in neonates. Only careful observation allows for proper diagnosis and appropriate treatment. Correct diagnosis is essential for optimal postnatal treatment.

KEY WORDS:
Cushing’s syndrome, infant, suprarenal tumour.

INTRODUCTION

The incidence of neonatal suprarenal masses has increased in the last decade due to the expanded use of pre- and postnatal ultrasonography. Differential diagnoses of these masses included benign and malignant diseases such as neonatal adrenal haemorrhage/haematoma (NAH), neuroblastomas (NBLs), cysts, subdiaphragmatic extralobar pulmonary sequestration, and adrenocortical tumours (ACTs) [1, 2].

Among such diseases, NAH is the most common, with an incidence estimated between 1 : 400 to 3 : 100,000 live-born newborns [2, 3]. Primary malignant tumours of the adrenal gland in children includes NBLs and ACTs [1, 2, 4–6]. The most common malignant tumours of suprarenal glands in neonates and infants are NBLs [1, 7].

In clinical practice, differential diagnosis of adrenal gland masses in newborns is limited to isolating the newborns with NBLs from the large group of newborns with NAH. Initially, other less frequent pathological changes in adrenal glands are not considered [4].

ACTs are rare among children. They occur with a frequency of 0.2% of all tumour types in patients below 18 years of age [8]. The incidence depends on latitude and varies across geographic regions, with a worldwide incidence of 0.3 per million, ranging from 0.1 in Hong-
Cushing's syndrome as a rare manifestation of adrenal tumours in infants – case report

Kong and Bombay to a remarkably high 3.4–4.2 per million in southern Brazil, which is due to the high incidence of specific germline or somatic TP53 mutations [8, 9]. Most children diagnosed with ACTs come from southern Brazil (79.5%), 13% are from the USA, and the remaining 7.5% live in other regions of the world [8–10]. The estimated incidence of ACTs is 0.4 per million during the first four years of life, and it decreases to 0.1 per million during the subsequent 10 years [8]. Most patients are under five years of age and 14% are patients over 14 years old. During the first four years of life ACTs arise from the fetal adrenal gland [11].

Approximately 90% of children with ACTs have clinical evidence of an endocrine syndrome. Due to their ability to produce hormones, adrenocortical tumours are often clinically manifested by virilisation (80%) and very rarely by Cushing's syndrome (5.5%), hyperoestrogenism (feminisation), or aldosteronism (Conn syndrome) [9, 11].

Due to the relatively low incidence, most paediatricians and paediatric oncologists see only a few or no cases of this disease. This presents considerable difficulties and diagnostic doubts, especially in the early stages of the child's life.

We report a case of six-week-old male infant with a congenital adrenocortical tumour of the left suprarenal gland and Cushing's syndrome. We present difficulties with proper diagnosis, and we emphasise differences in proceedings depending on the suprarenal gland tumour nature. We also provide an overview of the available literature.

CASE REPORT

On the day of admission to the hospital, patient was a six-week-old male infant, born on time in good general condition (Apgar 10). Due to umbilical cord compression during delivery, an abdominal ultrasound (US) was performed during the first days of life. The US revealed a hyperechogenic mass size 29 mm × 21 mm × 26 mm in the left adrenal gland without visible vascularisation. In the follow-up ultrasound, taken a few days later, the mass was slightly greater and was similar to an evolving haematoma. The child was observed, and a further follow-up ultrasound was recommended. During a follow-up examination after a month, the mass was still present with dimensions of 27 mm × 25 mm × 23 mm, and it then presented with flow under the CD option. Based on suspicion of NBL, the patient was sent to our department for further diagnostic examinations.

When the patient was admitted to the clinic, physical examination revealed general muscular hypotension and poor weight gain (birth weight [BW] 3350 g, at the age of six weeks 4200 g). The abdomen was soft and painless, with no perceptible pathological restraints. Apart from an elevated neuron-specific enolase (NSE) level (36.13 μg/l), the laboratory tests showed no changes. Catecholamine levels in urine did not deviate from normal levels. The MR of the abdomen showed a solid tumour, size of 27 mm × 16 mm × 23 mm in the location of the previously described lesion, which was undergoing moderate inhomogeneous enhancement of contrast. The entire clinical presentation suggested neuroblastoma. According to the Low and Intermediate Risk Treatment Protocol of the Neuroblastoma Societé Internationale d’Oncologie Pédia- trique European Neuroblastoma (SIOPEN) Study, which considers the age of the child (< 1 year), the size of the tumour, and local advancement of the disease, the patient was admitted for observation.

One month later, during follow-up, the child presented classical symptoms of Cushing's syndrome: general muscular hypotension, poor weight gain (4650 g), dry skin composition, rash on face and shoulders, facies lunata, and buffalo neck (Fig. 1). Blood pressure was between the 90th and 95th percentile. In laboratory tests, NSE was lower than in previous tests (16.36 μg/l); other parameters showed no significant abnormalities. Based on physical examination and endocrine tests, the child was diagnosed with Cushing's syndrome (Table 1). In the MR, the tumour had enlarged to 36 mm × 26 mm × 28 mm (Fig. 2).

Mixed-cell ACT was suspected based on the MR imaging and the results of the hormonal tests, which revealed the following: hypercortisolaemia, no rhythm of

TABLE 1. The results of the hormonal tests

|                | Cortisol 8:00 (nmol/l) | Cortisol 20:00 (nmol/l) | Braking test (nmol/l) | ACTH (pg/ml) | DHEA-S (μg/dl) | Androstenedione (ng/ml) | Testosterone (nmol/l) |
|----------------|------------------------|------------------------|-----------------------|--------------|-----------------|------------------------|-----------------------|
| A              | 668                    | 572                    | 518                   | 13.1         | > 1000          | 28.2                   | 10.13                 |
| B              | 386                    | –                      | –                     | 10           | 15              | 0.3                    | 0.32                  |

A – before treatment, B – after treatment, ACTH – adrenocorticotropic hormone, DHEA-S – dehydroepiandrosterone sulfate

FIGURE 1. The typical features of Cushing’s syndrome (facios lunata)
cortisol and adrenocorticotropic hormone (ACTH) secretion, no cortisol secretion inhibition with dexamethasone inhibition test, and high hormone-active androgen levels (Table 1, column A). There were no clinical signs of premature puberty. The patient was treated surgically at the age of five months. Histopathological examination revealed an ACT with moderate malignancy potential – microscopically no radical excision. The tumour was partially encapsulated, built of cells with focal atypia, and without infiltration of the fibrous capsule. Tumour cells in the tumour area with no capsule were seen in the resection's margin. Due to no angioinvasion in histopathological examination and the absence of metastases, the disease was assessed as grade I. The patient received intravenous hydrocortisone on the day of surgery to prevent adrenal cortex insufficiency after tumour removal. Then, oral supplementation was given in gradually reducing doses.

A few weeks after surgery during the follow-up visit, a significant improvement in the child’s general condition was seen: gradual weight gain, normalisation of muscle tone, and removal of other phenotypic features of Cushing’s syndrome. The results of the hormonal tests five days after surgery in comparison to results before the procedure are presented in Table 1, column B. There was an increased level of cortisol after the procedure results from the oral supplementation, which was given to prevent adrenal cortex insufficiency.

DISCUSSION

In recent years, the frequency of recognising lesions in adrenal glands in neonates and infants has increased rapidly due to the improvement of neonatal and paediatric care as well as greater access to ultrasound examinations. If lesions are limited to the adrenal gland and are small (< 5 cm in diameter), they are often asymptomatic. In these cases, according to the rules of the European Low and Intermediate Risk Neuroblastoma Protocol: A SI-OPEN Study, the child should be observed until week 48 [5]. In this case study, we could observe a malignant tumour. In contrast to the distribution of NBL (1 case/7000 live births) [12], ACTs are rare (3 cases/1,000,000) [1]. Most of them (90%) are hormonally active and have a clear clinical manifestation, which is virilisation in girls and gonadotropin-independent precocious puberty in boys [11]. It presents with pubic hair, clitoral hypertrophy, hirsutism (55%), Cushing’s syndrome (5.5%), and mixed hormonal disorders (29.2%), and the remainder of tumours are non-functional tumours (10.2%) [1, 11]. Much less frequently seen clinical signs are loss or lack of weight gain, a moon-like face, change of voice, and even convulsions [9]. Infants are more likely to show generalised obesity and muscle wasting [1].

ACTs are more common in girls (F : M = 1.6 : 1 to 3 : 1) and may be associated with other genetic disorders such as Beckwith-Wiedemann syndrome and hemihypertrophy. A medical history can provide information on the prevalence of adrenal tumours or others in the family, such as hepatocellular carcinoma. However, it is believed that most often these tumours occur sporadically [1, 9, 11]. These facts from history and physical examinations can be helpful in determining the diagnosis.

The rarity of ACTs in children can cause difficulties with diagnosis. Most of the available scientific papers describe individual cases observed for only a few years (Table 2) [8, 13–15].

On the other hand, the authors emphasise that ACTs are the most common cause of adrenal-dependent Cushing’s syndrome in neonates and infants [8, 16].

Cushing’s syndrome in children very rarely may be caused by ACTH ectopic excretion of tumours located in organs other than suprarenal gland. There are case reports of Cushing’s syndrome in children due to a sacrococcygeal teratoma and nephroblastoma [17–19]. Adrenal NBL may be responsible for paraneoplastic Cushing’s syndrome [18].

In most cases, ACT diagnosis is delayed. The median period from onset of first symptoms to time of diagnosis in infants is, on average, five months. Isolated Cushing’s syndrome occurs more often in the older age group (median 12.6 years) [11].

At the time of diagnosis, in 2/3 of cases, the disease is limited to the adrenal gland (stage I or II) [9].

The basic treatment for ACTs is surgery. However, because of the tumour’s tissue fragility, bursting of the capsule and outpouring of tumour contents is relatively frequent [9]. Patients with no possibility of radical resection undergo systemic treatment with mitotane monotherapy, multidrug chemotherapy, and radiotherapy [8–10, 20].

The presented case report shows that diagnosing adrenal gland lesions during the neonatal period can cause difficulties. In our patient, the adrenal gland mass was initially assessed as NAH and later as NBL. Only at a later age, when the patient demonstrated signs of Cushing’s syndrome, did it lead to the correct diagnosis.
TABLE 2. The references from recent years regarding Cushing's syndrome in infants [13–15]

| Authors          | Age (months) | Sex | Family history | Gestation week | Disease history | Birth weight (g) | Birth disease | Physical examination | Laboratory tests | MRI/CT results | Treatment | Histopathology | Follow |
|------------------|--------------|-----|----------------|----------------|----------------|------------------|----------------|----------------------|----------------|----------------|-----------|---------------|--------|
| Dutta et al. [13]| 23           | F   | No malignancy  | 39             | At term        | 3544             | BP 140/100 mm Hg| Moon face, buffalo hump, facial and back hirsutism, facial acne, greasy hair, no palpable mass | Midnight cortisol 796 nmol/l, ACTH < 5 ng/l, mean cortisol 728 nmol/l, loss of circadian rhythm, raised serum androgens, no suppression of cortisol in overnight dexamethasone suppression test | Right-side mixed solid/cystic suprarenal mass 6.8 mm × 6.5 mm, no vascular, hepatic or renal invasion, no metastases | Laparoscopic surgery, metyrapone preoperatively, complete removal of tumour with no spillage, maintenance hydrocortisol | Adrenocortical carcinoma with complete resection. | Gradual improvement in height and weight; no evidence of tumour in US |
| Fudge et al. [14]| 6            | F   | Non-contributory | At term        | Serum cortisol 240 mcg/dl, total testosterone 113 mg/dl, DHEA-S 340 mg/dl, ACTH < 5 ng/ml | Homogenous left adrenal mass 53 mm × 48 mm × 37 mm with distal borders | Moon face, facial acne, irritability, arrested linear growth, increased weight, BP 110/70 mm Hg, Tanner stage 2 | Right-side adrenocortical heterogeneity 36 mm × 35 mm × 38 mm; tumour thrombus into the inferior vena cava, no metastases | Midnight cortisol 726 nmol/l, mean cortisol 726 nmol/l, ACTH < 1 ng/ml, loss of circadian rhythm, raised serum androgens, no suppression of cortisol in overnight dexamethasone suppression test | Right-side adrenal heterogeneity 36 mm × 35 mm × 38 mm; tumour thrombus into the inferior vena cava, no metastases | Preoperatively ketoconazole, surgical excision of tumour and thrombus; hydrocortisol during and after surgery | Adrenocortical carcinoma without capsular and vascular invasion, 5–10% necrosis, spotty, acinar, nodular, calcification |
| Vieira and Brain [15] | 4            | F   | Maternal pregnancy-induced hypertension | At term        | Cortisol 41 mcg/dl | Moon face, chubby, protruding abdomen, increase weight, normal BP | Midnight cortisol 726 nmol/l, mean cortisol 726 nmol/l, ACTH < 1 ng/ml, loss of circadian rhythm, raised serum androgens, no suppression of cortisol in overnight dexamethasone suppression test | Homogenous left adrenal mass 53 mm × 48 mm × 37 mm with distal borders | Homogenous left adrenal mass 53 mm × 48 mm × 37 mm with distal borders | Preoperatively ketoconazole, laparotomy with excision of the adrenal mass, postoperatively hydrocortisone and fludrocortisone | Adrenal adenoma without vascular and capsular invasion | Normalisation of hormonal markers postoperatively | Normalisation of hormonal markers postoperatively |
CONCLUSIONS

In diagnosing adrenal lesions, not only NAH and NBL should be considered as possibilities but also very rarely occurring ACTs. Only performing a very thorough physical examination of the child and noticing abnormalities can lead to proper diagnosis.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Nadler EP, Barksdale EM. Adrenal masses in the newborn. Semin Pediatr Surg 2000; 9: 156-164.
2. Yao W, Li K, Xiao X, Zheng S, Chen L. Neonatal suprarenal mass: differential diagnosis and treatment. J Cancer Res Clin Oncol 2013; 139: 281-286.
3. Deeg KH, Bettendorf U, Hofmann V. Differential diagnosis of neonatal adrenal haemorrhage and congenital neuroblastoma by colour coded Doppler sonography and power Doppler sonography. Eur J Pediatr 1998; 157: 294-297.
4. Calisti A, Orsolo L, Molle P, et al. Neonatal adrenal masses: do we have reliable criteria for differential diagnosis and expectant management? Minerva Pediatr 2012; 64: 313-318.
5. European Low and Intermediate Risk Neuroblastoma Protocol: A SIOPEN Study. Version 3.0, 2011.
6. Mutlu M, Karagüzel G, Aslan Y, et al. Adrenal hemorrhage in newborns: a retrospective study. World J Pediatr 2011; 7: 355-357.
7. Fisher JPH, Tweddel DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med 2012; 17: 207-215.
8. Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2012; 351: 37-43.
9. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 2005; 45: 265-273.
10. Ru W, Yang M, Xu S, et al. Management and prognosis of adrenocortical tumors in children: can we find out an appropriate points-scoring system to predict prognosis? Pediatr Surg Int 2017; 33: 705-711.
11. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22: 838-845.
12. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83-103.
13. Dutta D, Jain R, Maisnam I, et al. Isolated Cushing’s syndrome in early infancy due to left adrenal adenoma: an unusual aetiology. J Clin Res Pediatr Endocrinol 2012; 4: 164-168.
14. Fudge EB, von Allmen D, Volmar KE, Calikoglu AS. Cushing Syndrome in a 6-Month-Old Infant due to Adrenocortical Tumor. Int J Pediatr Endocrinol 2009; 2009: 6874.
15. Vieira H, Brain C. Cushing syndrome associated with an adrenal tumour. BMJ Case Rep 2012; 2012: bcr201206685.
16. Tatsi C, Stratakis CA. Neonatal Cushing Syndrome: A Rare but Potentially Devastating Disease. Clin Perinatal 2018; 45: 103-118.
17. Segers H, van der Heyden JC, van den Akker ELT, et al. Cushing syndrome as a presenting symptom of renal tumors in children. Pediatr Blood Cancer 2009; 53: 211-213.
18. Espinasse-Holder M, Defachelles AS, Weill J, et al. Paraneoplastic Cushing syndrome due to adrenal neuroblastoma. Med Pediatr Oncol 2000; 34: 231-233.
19. Rydzewska M, Krawcuk-Rybak M, Zajkowska A, et al. Cushing’s syndrome in infancy due to ectopic ACTH secretion by a sacrococcygeal teratoma. J Pediatr Endocrinol Metab 2017; 30: 475-478.
20. Dall’Igna P, Vrgonec C, De Salvo GL, et al. Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries. J Pediatr Surg 2014; 49: 1367-1371.